The Latest

NOW AVAILABLE: For the U.S. Antiretrovirals (HIV) Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2017.

ViiV Healthcare took over the top spot from Gilead in terms of promotional volume received due to heavy promotion of Triumeq and, to a lesser extent, the introduction of Juluca. Education and support were the most common topics across brands, including the “Daily Charge” patient-directed app from Gilead and savings offers from the majority of products. Campaign themes were common, though most were primarily the same as prior quarters, with the exception of new imagery alongside Truvada’s HIV prevention campaign. ViiV was consistent in its promotion of Selzentry’s approval for pediatric patients and announced that an oral solution would be available in June 2017, while Merck continued to promote Isentress HD’s approval. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the Q3 2017 report.

Q3-2017-HIV

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

 

NOW AVAILABLE: For the European Spondyloarthropathies (PsA) Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2017.

The European Spondyloarthropathies for PsA market distributed 55 pieces in Q3, with Cosentyx and Humira going head-to-head, representing 44%, (22% each) of the promotional volume. New indication approvals, discount agreements, new dosages, safety, and HCP and patient support were the main promotional topics during this quarter. As with the psoriasis market, patient support took a center stage to promote convenience and therapy adherence along with the introduction of the 90 mg dose by Janssen’s Stelara. Campaign themes such as the “Two-Face” imagery for Celgene’s Otezla or Hospira’s “New Perspective” campaign for Inflectra were maintained from previous quarters. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

PsA-Q3-2017

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.
For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Psoriasis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2017.

The promotional volume for this quarter has decreased among the biologics for psoriasis as the approvals and market debut of biosimilars in Europe become important. Overall, this market circulated 44 pieces during Q3, with AbbVie’s Humira and Novartis’ Cosentyx capturing the highest percentage in promotional volume. Almost half of the analyzed brands made patient support as their priority in the promotional strategy by offering patient’s programs such as the “LillyPlus Psoriasis Program” for Taltz or the new Humira’s 40 mg/0.4 enhanced presentation to promote patient’s comfort and adherence to therapy. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Psosriais-Q3-2017

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.
For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Asthma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2017.

Overall, GSK’s Breo Ellipta was cited as the brand with the highest volume of promotional campaign content across all products analyzed within the asthma market. Breo Ellipta advertised the “Reach with Confidence” and “Is it time?” HCP campaigns along with a variety of formulary messages. Teva premiered AirDuo RespiClick’s “A little can do a lot”  launch campaign and positioned the brand  as having “the first and only authorized generic ICS/LABA.” Spiriva Respimat’s expanded indication for patients as young as 6 years old was announced alongside the “Balloon” campaign. AstraZeneca launched the unbranded “ILLUMINATEOSINOPHILS” campaign, which associated eosinophils as a direct cause of chronic inflammation in severe asthma. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Q3-2017-Asthma

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Biologics for Rheumatoid Arthritis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2017.

Pfizer maintained its promotional leadership in terms of the proportion of materials received for Xeljanz and Xeljanz XR, followed closely by newcomer Kevzara from Sanofi Genzyme and Regeneron. This market expanded further during this time with the approval of Boehringer Ingelheim’s Cyltezo and Merck’s announcement of the availability of Renflexis. Campaign themes were common across brands, with new imagery noted from Amgen for Enbrel and Janssen’s Simponi ARIA. Pfizer also premiered a new campaign for Inflectra as it stressed cost savings over Remicade, and a new head-to-head noninferiority study for Xeljanz was distributed. Education and support were priority topics, with the vast majority of materials directed to healthcare professionals. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the Q3 2017 report.

Q3-2017-RA

 

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Biologics for Psoriasis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2017.

A consistent 75 new materials were received during this quarter within the biologics for psoriasis market. Janssen’s Tremfya significantly increased its number of promotions to tie with Lilly’s Taltz for the largest promotional volume. Tremfya’s FDA approval was advertised in several HCP materials, and it was noted that the brand will now be part of the Janssen Link program. More biosimilars entered the market with the approval of Boehringer Ingelheim’s Cyltezo and the recent availability of Merck’s Renflexis. Abbvie premiered the empowering “Humira & Go” DTC campaign and Celgene’s new HCP campaign emphasized Otezla’s convenient, oral formulation compared to topicals and injections. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Q3-2017-Biologics-for-Psori

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

Trokendi-XR

Supernus Pharmaceuticals has launched a new “Emoji” style campaign for Trokendi XR to display how migraine patients receiving 100 mg/day or less of topiramate aren’t experiencing its full potential. This campaign encouraged physicians to try for more migraine prevention by converting their immediate-release topiramate patients to once-daily Trokendi XR.

Additional examples of promotional campaigns are available with a subscription to CD Promo WorldWide. Contact Christine Alongi at alongi@dtwresearch.com for more information.

NOW AVAILABLE: For the Immunoglobulin Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Overall, 16 new pieces were received for the Immunoglobulin therapy market during the second quarter, showing a 45% increase in promotional volume from Quarter 1. The leader of promotional distribution shifted from Grifols’s Gamunex-C to CSL Behring’s Hizentra during this quarter. Shire’s DTC campaign for Cuvitru continued to inspire patients to take control of their treatment and fight back against PI. CSL Behring promoted its two Ig products, Hizentra and Privigen, as the leading Ig therapies. Additional insights into marketing strategies and channel utilization across all PI brands are available in the full Q2 report.

Q2-2017-Immuno

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online  database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more. Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com  \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Immune Thrombocytopenic Purpura (ITP) Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017

Overall, 16 new pieces were received across the brands observed within the ITP market, presenting a 45% increase from Q1. This increase featured the addition of Rigel Pharmaceuticals’ Tavalisse, which included press releases announcing its proprietary name and New Drug Application status. Novartis’s Promacta continued to hold the largest share of promotional volume between all brands, acquiring 69% in total. Within Promacta’s analysis, a new visual campaign featured a woman walking across a bridge of platelets to symbolize long-term response. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-ITP

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online  database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com  \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

 NOW AVAILABLE: For the Vaccines Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

When taking a look at distributional volume between five corporations in the vaccines market, the majority of marketing materials were received for Merck, comprising 27% of the 51 new pieces received. Of the 51 new pieces received, 29% were indicated for pneumonia. Highlights for each indication are as follows:

  • HPV: Merck’s Gardasil 9 presented the “One Less” DTC campaign, which highlighted HPV-related cancer prevention.
  • Flu: Sanofi distributed the most pieces, which highlighted Fluzone High-Dose’s familiar “Defense” campaign and support with the Fluzone Partners Program.
  • Meningitis: GlaxoSmithKline produced the most pieces and featured the new Bexsero “Fast” campaign, which emphasized Bexsero’s fast series completion.
  • Pediatric vaccines: Sanofi provided a guide to implementing a Pentacel and Quadracel vaccine schedule.
  • Pneumonia: Merck’s Pneumovax 23 and Pfizer’s Prevnar 13 produced an equal number of pieces this quarter.
  • Shingles: Merck’s Zostavax encouraged patients and healthcare professionals to vaccinate with Zostavax.

Additional insights into marketing strategies and channel utilization are available in the full Q2 report.Q2-2017-Vaccine-CorpQ2-2017-Vaccine-Indications

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com